Targeting genes involved with drug metabolism and transport pathways
PGx testing (pharmacogenetic analysis) is performed to provide information for clinicians prescribing medication for patients. The University of Arizona Genetics Core for Clinical Services pharmacogenetics panel targets 61 variable sites within 18 different genes involved with drug metabolism and transport pathways. DNA is isolated from a patient cheek swab and genomic regions containing the various polymorphic sites are amplified and subsequently tested using the Agena MassArray™ platform. The allelic status of each site is then recorded and results are converted into a patient haplotype profile. These haplotype profiles can be used to assess the metabolic status of known drug classes and specific medications for each individual patient
- The DNA is isolated from patient check swab samples.
- DNA is both amplified and extended in separate reactions via the Agena PGx 74 kit™ for downstream analysis on the Agena MAssArray™ platform to generate patient genotypes.
- The patient genotypes are converted to a haplotype profile for use in determining metabolic status of the patient.